Two Hands Corp (TWOH)

[Carjockey2]

Why did TWOH bring on Dr. Daniel Reshefs?

>>>His expertise aligns with Two Hands Corporation’s (TWOH) strategic objectives in several key ways, particularly as the company expands into the healthcare and pharmaceutical sectors. Here’s how:

🔬 1. Advancing Pharmaceutical Development

TWOH’s Strategy: The company has shown intent to evolve from a family-focused product business into a healthcare or biotech entity through acquisitions and partnerships.

Reshef’s Value:
Dr. Reshef brings over 25 years of pharmaceutical development experience, including leadership of Phase I–IV clinical trials, regulatory affairs, and drug safety operations. This is directly aligned with the kind of R&D and regulatory navigation TWOH will require if it launches or acquires pharmaceutical products.

🌍 2. Global Network for Expansion

TWOH’s Strategy: TWOH has signaled interest in international partnerships, especially in biotech innovation hubs like Israel.

Reshef’s Value:
As a dual U.S.-Israeli citizen with deep ties to Israeli research institutions and global pharma companies (e.g., Roche, Genentech, Bristol-Myers Squibb), Reshef provides an immediate bridge to global biotech ecosystems and investors.

🧬 3. Clinical and Regulatory Expertise

TWOH’s Strategy: To gain credibility and secure approvals in the health sector, the company will need to understand and navigate complex clinical and regulatory processes.

Reshef’s Value:
His academic background (M.D., MPH, Ph.D. in Epidemiology from Johns Hopkins) and his past roles in regulatory and medical affairs equip him to advise on:
•FDA and EMA pathways
•Trial design
•Pharmacovigilance
This guidance is critical for launching any therapeutic assets or health-based technologies.>>>